MDR is being priced as MedAdvisor and not MedAdvisor with Adheris.
Anyone buying before the June quarter results is extremely brave.
There's a number of announcements to get through that might steady the ship:
- Replacement CEO. They are targeting a US based Exec.
- What calibre resource will they get to manage an ASX listed healthcare stock?
- Final earn-out to Syneos in September.
- How will this be funded? Cash, CR, PFG?
Better numbers in June is needed, else they will require a number of quarters to regain trust.
- Any and I mean any price sensitive news that confirms an extension to or new revenue stream.
- It's all well and good to simply publish quarterlies, if you're meeting your revenue targets.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.35M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 19999 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 20000 | 1 |
View Market Depth
| Last trade - 07.32am 25/06/2025 (20 minute delay) ? |
| MDR (ASX) Chart |
Day chart unavailable